Activated protein C improves macrovascular and microvascular reactivity in human severe sepsis and septic shock

Shock

Volumn 40, Issue 6, 2013, Pages 512-518

  Favory, Raphaël ^a   Poissy, Julien ^a   Alves, Isabelle ^a   Guerry, Mary Jane ^a   Lemyze, Malcolm ^a   Parmentier Decrucq, Erika ^a   Duburcq, Thibault ^a   Mathieu, Daniel ^a  

^a UNIV LILLE   (France)

Author keywords

activated protein C; laser Doppler; microcirculation; phenylephrine; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; PHENYLEPHRINE;

ADULT; AGED; ANTICOAGULATION; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; HYPEREMIA; LASER DOPPLER FLOWMETRY; MALE; PROTEIN SYNTHESIS; SEPSIS; SEPTIC SHOCK; SYMPATHETIC TONE;

ADULT; AGED; ARTERIAL PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; PHENYLEPHRINE; PROSPECTIVE STUDIES; PROTEIN C; SEPSIS; SHOCK, SEPTIC; SKIN; VASOCONSTRICTOR AGENTS;

EID: 84888137840     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000060     Document Type: Article

References (41)

1. Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 31(3):946-955, 2003.
2. Guc MO, Furman BL, Parratt JR: Endotoxin-induced impairment of vasopressor and vasodepressor responses in the pithed rat. Br J Pharmacol 101(4): 913-919, 1990.
3. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 259(4 Pt 2):H1038YH1043, 1990.
4. Ince C: The microcirculation is the motor of sepsis. Crit Care 9(Suppl 4): S13YS19, 2005.
5. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL: Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32(9):1825-1831, 2004.
6. Knotzer H, Maier S, Dunser M, Stadlbauer KH, Ulmer H, Pajk W, Hasibeder WR: Oscillation frequency of skin microvascular blood flow is associated with mortality in critically ill patients. Acta Anaesthesiol Scand 51(6):701-707, 2007.
7. Neviere R, Mathieu D, Chagnon JL, Lebleu N, Millien JP, Wattel F: Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis. Am J Respir Crit Care Med 153(1):191-195, 1996.
8. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166(1): 98-104, 2002.
9. Creteur J, Carollo T, Soldati G, Buchele G, De Backer D, Vincent JL: The prognostic value of muscle StO2 in septic patients. Intensive Care Med 33(9): 1549-1556, 2007.
10. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL: The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34(2): 403-408, 2006.
11. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34(7):1918-1924, 2006.
12. Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 361(27): 2646-2652, 2009.
13. Levi M, van der PT: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 11(Suppl 5):S3, 2007.
14. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28(7): 2209-2216, 2000.
15. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79(3):918-925, 1987.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699-709, 2001.
17. Favory R, Lancel S, Marechal X, Tissier S, Neviere R: Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Med 32(6):899-905, 2006.
18. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K: Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104(10):1171-1175, 2001.
19. Wang Z, Su F, Rogiers P, Vincent JL: Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 35(11): 2594-2600, 2007.
20. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL: Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31(11):1573-1576, 2005.
21. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, et al. : Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29(6):894-903, 2003.
22. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31(3):834-840, 2003.
23. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 32(4):1011-1017, 2004.
24. Isobe H, Okajima K, Harada N, Liu W, Okabe H: Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. J Thromb Haemost 2(2):313-320, 2004.
25. Keller SA, Moore CC, Clemens MG, McKillop IH, Huynh T: Activated protein C restores hepatic microcirculation during sepsis by modulating vasoregulator expression. Shock 36(4):361-369, 2011.
26. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, Decoster B, Zerimech F, Neviere R: Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 29(5):572-576, 2008.
27. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. : Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32(3):858-873, 2004.
28. Bellissant E, Annane D: Effect of hydrocortisone on phenylephrineYmean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 68(3):293-303, 2000.
29. Lamblin V, Favory R, Boulo M, Mathieu D: Microcirculatory alterations induced by sedation in intensive care patients. Effects of midazolam alone and in association with sufentanil. Crit Care 10(6):R176, 2006.
30. Rossi M, Carpi A, Di Maria C, Franzoni F, Galetta F, Santoro G: Skin blood flowmotion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases. Physiol Res 58(1): 39-47, 2009.
31. BhattacharyaA, Grinnell BW, CohenML: Unlike thrombin, protein C and activated protein C do not affect vascular tone. Peptides 21(8):1231-1236, 2000.
32. Hoen S, Mazoit JX, Asehnoune K, Brailly-Tabard S, Benhamou D, Moine P, Edouard AR: Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock. Crit Care Med 33(12): 2737-2743, 2005.
33. Nacira S, Meziani F, Dessebe O, Cattan V, Collin S, Montemont C, Gibot S, Asfar P, Ramaroson A, Regnault V, et al. : Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 37(1): 246-255, 2009.
34. Gupta A, Berg DT, Gerlitz B, Richardson MA, Galbreath E, Syed S, Sharma AC, Lowry SF, Grinnell BW: Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension. Shock 28(4):468-476, 2007.
35. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW: Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 20(2):267-277, 2009.
36. Toltl LJ, Swystun LL, Pepler L, Liaw PC: Protective effects of activated protein C in sepsis. Thromb Haemost 100(4):582-592, 2008.
37. O'Brien LA, Richardson MA, Mehrbod SF, Berg DT, Gerlitz B, Gupta A, Grinnell BW: Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR-independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol 27(12):2634-2641, 2007.
38. Macarthur H, Westfall TC, Riley DP, Misko TP, Salvemini D: Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci U S A 97(17):9753-9758, 2000.
39. de Wit C, Bolz SS, Kaas J, Pohl U: Myogenic effects enhance norepinephrine constriction: inhibition by nitric oxide and felodipine. Kidney Int Suppl 67: S122YS126, 1998.
40. Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK Cooper LM: Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs. Curr Med Res Opin 23(1):235-244, 2007.
41. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, et al. : Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055-2064, 2012.